

## By the Numbers

Sterile Injectables revenues increased **23%** to full-year sales of **\$654** million

Endo's total 2017 revenue was **\$3.47** billion

Endo has approximately **3,000** employees worldwide

U.S. Specialty Branded Pharmaceuticals performance increased **11%** to full-year sales of **\$453** million

XIAFLEX® achieved full-year sales of **\$213** million, a **12%** increase vs. prior year

U.S. Generic Pharmaceuticals has a portfolio of over **280** product families

Endo announced the initiation of **two** pivotal Phase 3 clinical trials of collagenase clostridium histolyticum (CCH) for the treatment of cellulite. Cellulite has been reported in **85% to 98%** of post-pubertal females and affects women of all races and ethnicities

U.S. Generic Pharmaceuticals has over **175** products in our pipeline including approximately **100** ANDAs pending with the FDA, of which more than **1/3** represent first-to-file or first-to-market opportunities